Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic HER2-mutated NSCLC By Ogkologos - November 14, 2025 71 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SOHO-01 study Source RELATED ARTICLESMORE FROM AUTHOR Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off MOST POPULAR FDA Approves Imlunestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... October 10, 2025 An Updated Overview of Estimates for Cancer Incidence and Mortality in... June 23, 2022 EMA Recommends Granting a Marketing Authorisation for a Biosimilar Bevacizumab, Onbevzi November 23, 2020 What to Know About Using Activated Charcoal During Cancer December 21, 2023 Load more HOT NEWS Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors Maintenance Rucaparib for Platinum-Sensitive Pancreatic Adenocarcinoma with HRD-Associated Mutations A More Treatable Kind of Metastatic Cancer? Why it’s difficult to estimate the number of extra cancer deaths...
